MedPredict's Rheumatology Panel Analyzes Rheumatoid Arthritis, Lupus and Gout Markets and Pipelines Following ACR Conference

Friday, November 21, 2008 General News J E 4
SCOTTSDALE, Ariz., Nov. 20 MedPredict Market Research, aglobal provider of pharmaceutical competitive intelligence and marketresearch, has published a new report providing critical strategic insight forpharma and biotech companies with a stake in the market for RheumatoidArthritis (RA), lupus and gout therapies.

In this report, entitled Thought Leader Insight & Analysis: RheumatoidArthritis, MedPredict's global Thought Leader Panel reviews key data presentedat the recent American College of Rheumatology annual meeting. According toDr. Jeffrey Berk, MedPredict's president, "Much of the focus at ACR 2008 wason new oral pharmacotherapies, including Jak, Syk and other mechanisms. Ourpanel reviews these data and provides insight into how these drugs will serveunmet needs in the specialty and primary care environments."

The panelists also provide their perspectives on new marketing initiativesand competitive dynamics amongst the anti-TNF drugs, including preferencesbetween certolizumab and golimumab, and insights into opportunities for a trueoral anti-TNF. The Panel also discusses the pharmacoeconomics of these drugsin comparison with other therapeutic options, and predicts the course ofdevelopment of generic/biosimilar anti-TNFs.

This report also includes an in-depth look at new pharmacotherapies forthe prevention or treatment of gout. "The incidence of gout is clearlyincreasing as the age and number of patients with chronic illness, metabolicsyndrome/obesity and transplants rises," according to Dr. Berk. "The societalcost of the disease is significant: in men, gout is now the most commoninflammatory disorder."

Companies mentioned in this report include: Abbott, Amgen, Amgen/Wyeth,Ardea, Arana, AstraZeneca/MedImmune, Biogen, Bristol-Myers Squibb, Celgene,Centocor, Centocor/Schering-Plough/Essex, Dr. Reddy's, GlaxoSmithKline/Genmab,Human Genome Sciences, Incyte, J&J/Alza, Medac, Merck, MerckSerono/ZymoGenetics, Nitec/SkyePharma, Novartis/Medarex, Oxypharma, Pfizer,Regeneron, Rigel, Roche/Chugai, Roche/Genentech, Sanofi-Aventis,Sanofi-Aventis/Regeneron, Savient, Teijin/Ipsen/Takeda Abbott Pharmaceuticals,UCB, Vertex, Wyeth/TMRC, Wyeth/Trubion, and Xoma.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict ( maintains a proprietary database ofover 1,000 global physician thought leaders, including 40+ specialties in 30+therapeutic categories. Based on primary interviews with these thoughtleaders, MedPredict publishes periodic reports in each category to keepclients up-to-date on emerging trends and competitive activity. The reportsinclude thought leader reactions to recent publications and medicalconferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Photos: Peptides Discovered to Alleviate Chemother...
MicroPhage Closes Latest Financing